Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ETT Completes First-in-Human Cases With its Endomina Triangulation Platform

Published: Friday, October 05, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Results confirm the safety and efficacy of the device and will lead to an extended clinical trial in 2013 at four key centers in Europe.

Endo Tools Therapeutics has announced the completion of several first-in-human cases where Endo Tools' new Endomina™ triangulation platform has been used.

Endomina is a universal platform that adds triangulation to any endoscope and that can be used with any endoscopic tool available for gastro-enterologists. It allows the surgeons to perform complex movements and to use multiple tools.

Dr Vincent Huberty and Dr Mostafa Ibrahim, both from Erasme hospital in Brussels, Belgium, first used Endomina to perform complex tissue resection and anterior-posterior tissue apposition in various models.

The device was then used on four patients in April, May, July and September 2012. The first two patients showed the safety of the device and highlighted the differences between all models done previously and real patients.

For the two other patients, the team, led by Prof. Jacques Deviere, chairman of the department of gastroenterology, was able to perform a full-thickness suture in the stomach, showing its potential for pouch reduction.

It allowed the surgeons to perform all the acts and validate the functionality of the device. All patients were released after a maximum of two days.

Endomina is an innovative device that adds multiple degrees of freedom and therapeutic channels to a conventional endoscope, a device that allows surgeons to look inside the body.

It gives full freedom to gastro-enterologists to perform manipulations that were until now only possible through laparoscopic access, often referred to as "keyhole surgery".

The devices open new opportunities for advances in flexible endoscopy, and for treatment of major diseases such as obesity, type II diabetes or gastro-intestinal tract tumors.

For the patient, the use of Endomina induces reduced hospitalization and improved comfort, due to lower anesthesia requirement. For hospitals and social security systems, it means a reduced overall intervention cost.

"For years, therapeutic endoscopists have been one-armed surgeons. Endomina offers the opportunity to work with two hands and therefore to do simple things like lifting tissue or making a knot, which have not been possible up to now," said Prof. Jacques Deviere, chairman of the department of gastroenterology. "I think it is a first step towards real endoluminal surgery."

The Erasme clinical trial, focused on morbid obesity treatment, will soon be expanded to four other key centers in Europe with a target of 50 patients in 2013.

To treat morbid obesity, surgeons usually perform a restrictive surgery of the stomach. There are more than 200,000 such procedures per year in the EU, representing a market of EUR two billion.

"The initial feedback about Endomina has been outstanding and many key clinicians who have been introduced to our technology are excited about its potential for new endoluminal surgery," said Alexandre Chau CEO of Endo Tools Therapeutics.

Chau continued, "We are in the process of raising funds to get to the next step of our development and put the device on the market in the EU."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Endo Tools Therapeutics Secures EUR 2.5 Million in Second Round Funding
The investment provides Endo Tools Therapeutics with funding for clinical trials in obesity treatment, to take place in 2013 and 2014.
Wednesday, September 11, 2013
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos